DOV-102,677 is a psychoactive drug being developed by Merck and is currently in clinical trials. It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the (−)-enantiomer of DOV-216,303, and its (+)-enantiomer is DOV-21,947 (amitifadine). Instead of being developed for depression, DOV-102,677 is being developed for the treatment of alcoholism. IC50 values for the SERT, NET and DAT are 129 nM, 103 nM, and 133 nM.
| Property |
Value |
| dbo:abstract |
DOV-102,677 is a psychoactive drug being developed by Merck and is currently in clinical trials. It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the (−)-enantiomer of DOV-216,303, and its (+)-enantiomer is DOV-21,947 (amitifadine). Instead of being developed for depression, DOV-102,677 is being developed for the treatment of alcoholism. IC50 values for the SERT, NET and DAT are 129 nM, 103 nM, and 133 nM. DOV-102,677 (20 mg/kg IP) increased extracellular levels of dopamine and serotonin in the prefrontal cortex to 320 and 280% above baseline 100 min after administration. Dopamine levels were stably increased for the duration (240 min) of the study, but serotonin levels declined to baseline by 200 min after administration. Norepinephrine levels increased linearly to a maximum of 348% at 240 min post-dosing. (en) |
| dbo:casNumber |
410074-75-8 |
| dbo:chEMBL |
488638 |
| dbo:fdaUniiCode |
NS8NWQ6NF4 |
| dbo:pubchem |
11637190 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/DOV-102677.svg?width=300 |
| dbo:wikiPageID |
22604153 (xsd:integer) |
| dbo:wikiPageLength |
3899 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1121586392 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Psychoactive_drug dbr:Depression_(mood) dbr:Dopamine_transporter dbc:Chloroarenes dbc:Cyclopropanes dbr:Clinical_trials dbr:Alcoholism dbr:Amitifadine dbr:DOV-216,303 dbr:Drug_development dbc:Serotonin–norepinephrine–dopamine_reuptake_inhibitors dbr:Merck_&_Co. dbr:Serotonin_transporter dbr:IC50 dbr:Norepinephrine_transporter dbr:Serotonin-norepinephrine-dopamine_reuptake_inhibitor dbr:File:DOV_stereochemistry.svg |
| dbp:c |
11 (xsd:integer) |
| dbp:casNumber |
410074 (xsd:integer) |
| dbp:chembl |
488638 (xsd:integer) |
| dbp:chemspiderid |
9811932 (xsd:integer) |
| dbp:cl |
2 (xsd:integer) |
| dbp:h |
11 (xsd:integer) |
| dbp:iupacName |
-1 (xsd:integer) |
| dbp:legalUs |
Investigational New Drug (en) |
| dbp:n |
1 (xsd:integer) |
| dbp:pubchem |
11637190 (xsd:integer) |
| dbp:smiles |
C1[C@@H]2[C@]1C3=CCCl (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
BSMNRYCSBFHEMQ-GZMMTYOYSA-N (en) |
| dbp:unii |
NS8NWQ6NF4 (en) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
407870872 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:width |
170 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Clear_left dbt:Drugbox dbt:Psychoactive-stub dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite dbt:Drugs_used_in_addictive_disorders dbt:Monoamine_reuptake_inhibitors |
| dcterms:subject |
dbc:Chloroarenes dbc:Cyclopropanes dbc:Serotonin–norepinephrine–dopamine_reuptake_inhibitors |
| gold:hypernym |
dbr:Drug |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatCyclopropanes yago:WikicatSerotonin-norepinephrine-dopamineReuptakeInhibitors yago:Agent114778436 yago:Anesthetic102710766 yago:CausalAgent100007347 yago:Cyclopropane103155661 yago:Drug103247620 yago:GeneralAnesthetic103433434 yago:InhalationAnesthetic103570838 yago:Inhibitor114724436 yago:Matter100020827 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090 umbel-rc:DrugProduct |
| rdfs:comment |
DOV-102,677 is a psychoactive drug being developed by Merck and is currently in clinical trials. It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the (−)-enantiomer of DOV-216,303, and its (+)-enantiomer is DOV-21,947 (amitifadine). Instead of being developed for depression, DOV-102,677 is being developed for the treatment of alcoholism. IC50 values for the SERT, NET and DAT are 129 nM, 103 nM, and 133 nM. (en) |
| rdfs:label |
DOV-102,677 (en) |
| owl:sameAs |
freebase:DOV-102,677 yago-res:DOV-102,677 wikidata:DOV-102,677 https://global.dbpedia.org/id/4iXDh |
| prov:wasDerivedFrom |
wikipedia-en:DOV-102,677?oldid=1121586392&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/DOV-102677.svg wiki-commons:Special:FilePath/DOV_stereochemistry.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:DOV-102,677 |
| is dbo:wikiPageRedirects of |
dbr:DOV-102677 dbr:DOV_102,677 |
| is dbo:wikiPageWikiLink of |
dbr:List_of_adrenergic_drugs dbr:List_of_dopaminergic_drugs dbr:Amitifadine dbr:DOV-216,303 dbr:C11H11Cl2N dbr:DOV-102677 dbr:DOV_102,677 dbr:Serotonin–norepinephrine–dopamine_reuptake_inhibitor |
| is foaf:primaryTopic of |
wikipedia-en:DOV-102,677 |
